Mizuho Securities Raises Price Target on Jazz Pharmaceuticals (JAZZ) Ahead of 2Q

Mizuho Securities reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and raised the price target to $195.00 (from $193.00), ahead of 2Q. Mizuho model revenues of $361.7M and EPS of $2.76 relative to consensus estimates $376.2M and $2.80.

Analyst Irina Koffler commented, "We reiterate our Buy rating on JAZZ heading into 2Q:16 due to continued optimism about the Xyrem litigation/settlements and stronger than expected performance of Defitelio in the U.S. We raise our PT to $195 from $193."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $142.51 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Bank Jago Tbk PT (ARTO:IJ) to Overweight
• ASML Holding NV (ASML:NA) (ASML) PT Raised to EUR1,100 at Berenberg
• Morgan Stanley Downgrades Etsy (ETSY) to Underweight